ACAD.OQ
Latest Trade
45.87USDChange
0.80(+1.78%)Volume
120,561Today's Range
-
46.3152 Week Range
-
47.77As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 45.07 |
|---|---|
Open | 45.25 |
Volume | 120,561 |
3M AVG Volume | 44.68 |
Today's High | 46.31 |
Today's Low | 45.10 |
52 Week High | 47.77 |
52 Week Low | 14.01 |
Shares Out (MIL) | 153.54 |
Market Cap (MIL) | 6,941.93 |
Forward P/E | -28.49 |
Dividend (Yield %) | -- |
ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results
Acadia Pharmaceuticals Prices Underwritten Public Offering Of 6.25 Mln Shares At $40/Shr
Acadia Pharmaceuticals - Intends To Offer And Sell $250 Million Of Its Common Stock
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
Industry
Biotechnology & Drugs
Executive Leadership
Stephen R. Biggar
Independent Chairman of the Board
Srdjan Stankovic
President
Stephen R. Davis
Director and Chief Executive Officer
Elena H. Ridloff
Executive Vice President, Chief Financial Officer
Austin D. Kim
Executive Vice President, General Counsel, and Secretary
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 23.12 |
Price To Book (MRQ) | 10.04 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -53.71 |
Return on Equity (TTM) | -48.00 |
Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.
Acadia Pharmaceuticals Inc said on Monday its add-on treatment for schizophrenia failed to meet the main goal in a late-stage study.
* ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS
* ACADIA PHARMACEUTICALS SAYS CEO STEPHEN DAVIS'S FY 2017 TOTAL COMPENSATION WAS $15.2 MILLION, INCLUDING $13.9 MILLION IN OPTION AWARDS - SEC FILING Source : https://bit.ly/2ra1j3J Further company coverage: (Reuters.Briefs@thomsonreuters.com)
The U.S. Food and Drug Administration said on Wednesday it was reviewing Acadia Pharmaceuticals' Parkinson's medication, the only approved drug used to treat hallucinations and delusions associated with the disease.
* ACADIA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS
* Acadia Pharmaceuticals reports third quarter 2017 financial results
* Acadia Pharmaceuticals initiates phase III study of Pimavanserin in dementia-related psychosis
Several big-name hedge fund investors trimmed their stakes in healthcare companies in the second quarter as the sector led the broad U.S. stock market higher, rallying amid a Republican effort to repeal and replace President Obama's signature healthcare law.
* Acadia pharmaceuticals reports second quarter 2017 financial results
* ACADIA Pharmaceuticals Inc - expects that full-year NUPLAZID net sales for 2017 will be between $105 million and $115 million
* Acadia Pharmaceuticals reports financial results for the fourth quarter and year ended december 31, 2016
Acadia Pharmaceuticals Inc said on Tuesday its drug to treat psychosis in patients suffering from Alzheimer's disease met its main goal in a mid-stage study, sending its shares up as much as 18.5 percent.
* Acadia Pharmaceuticals initiates phase II trial of Pimavanserin for adjunctive treatment in patients with negative symptoms of schizophrenia Source text for Eikon: Further company coverage:
UK's Competition and Markets Authority (CMA):
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.